Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates

A method of treating cancer in an individual comprising administering to the individual a compound of Formula I at a dose of between 3 mg/kg to 30 mg/kg, wherein the compound of Formula I comprises an anti-CD22 antibody (Ab) and an immunomodulating oligonucleotide (P)

• wherein the Ab comprises two antibody light chains, two antibody heavy chains, and two Q-tag peptides (Q);
• wherein each of the two Q-tag peptides comprises the amino acid sequence RPQGFGPP (SEQ ID NO:2);
• wherein one Q-tag peptide is linked to the C-terminus of each of the two antibody heavy chains;
• wherein one of the two Q-tag peptides is linked to the immunomodulating oligonucleotide via an amide bond with the glutamine residue of the Q-tag peptide and a linker (L) as shown in Formula (A):
• wherein indicates the point of attachment of Q to the antibody (Ab);
• wherein each heavy chain of the Ab comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:6, a CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a CDR3 comprising the amino acid sequence of SEQ ID NO:8, and each light chain of the Ab comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:9, a CDR2 comprising the amino acid sequence of YTS, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
• 11;
• wherein the linker L is
• wherein m is 24, and wherein † indicates the point of attachment to the oligonucleotide P, and ‡ indicates the point of attachment to the glutamine residue of the Q-tag;
• and
• wherein the oligonucleotide P comprises the structure:
• or a pharmaceutically acceptable salt thereof,
• wherein * and ** indicate the points of attachment within the oligonucleotide,
• wherein † indicates the point of attachment to the linker L.